世界の糖尿病網膜症市場2023-2030:種類別(増殖性DR、非増殖性DR)、管理別(眼内ステロイド注射、レーザー手術、硝子体手術)、地域別

【英語タイトル】Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-proliferative DR), By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料(GRV23JUN039)・商品コード:GRV23JUN039
・発行会社(調査会社):Grand View Research
・発行日:2023年5月15日
・ページ数:120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,360,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社の市場調査書によると、世界の糖尿病網膜症市場規模が、予測期間中(2023年~2030年)に年平均6.4%増加し、2030年までに137.7億ドルへ達すると見込まれています。本調査書では、糖尿病網膜症の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、種類別(増殖性糖尿病網膜症、非増殖性糖尿病網膜症)分析、管理別(抗VEGF療法、眼内ステロイド注射、レーザー手術、硝子体手術)分析、地域別(北米、ヨーロッパ、アジア太平洋中南米、中東・アフリカ)分析、競争状況などについて調査・分析し、まとめています。なお、こちらに掲載されている企業情報には、Bayer AG、Allergan plc、Novartis AG、Oxurion NV、Sirnaomics, Inc.、Genetech、Alimera Sciences、Ampio Pharmaceuticals、BNC Peptides、Kowa Company, Ltd.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界糖尿病網膜症の市場規模:種類別
- 増殖性糖尿病網膜症の市場規模
- 非増殖性糖尿病網膜症の市場規模
・世界糖尿病網膜症の市場規模:管理別
- 抗VEGF療法の市場規模
- 眼内ステロイド注射の市場規模
- レーザー手術の市場規模
- 硝子体手術の市場規模
・世界糖尿病網膜症の市場規模:地域別
- 北米の糖尿病網膜症市場規模
- ヨーロッパの糖尿病網膜症市場規模
- アジア太平洋の糖尿病網膜症市場規模
- 中南米の糖尿病網膜症市場規模
- 中東・アフリカの糖尿病網膜症市場規模
・競争状況

糖尿病網膜症市場の成長と動向

Grand View Research社の最新レポートによると、世界の糖尿病性網膜症市場規模は、2023年から2030年までの年平均成長率(CAGR)6.4%を記録し、2030年までに137.7億米ドルに達すると予測されています。糖尿病の罹患率は劇的に増加しています。国際糖尿病連合によると、2021年の糖尿病患者数は約5億3,700万人で、2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測されています。糖尿病は人々の失明の主要な原因の一つです。失明は網膜血管の漏れや破裂によって引き起こされ、病期によって永久的なものと一時的なものがあります。調査によると、2020年の糖尿病性網膜症の患者数は約1億312万人で、2045年には1億6,050万人に達すると予想されています。

患者の意識レベルの上昇や医療費の増加も、市場成長を促進する要因のひとつです。さらに、先進国と発展途上国の両方で老年人口が増加していることも、予測期間中に市場を促進すると予想されます。Population Reference Bureauの「Aging in the United States(米国における高齢化)」と題するレポートによると、米国における65歳以上の高齢者数は、2016年の約4,600万人から2060年には9,800万人以上に増加すると予測されています。糖尿病網膜症の早期発見・治療ガイドラインは、COVID-19パンデミック関連の制約により大幅に減少していました。2019年と比較すると、糖尿病網膜症に対する硝子体内注射はパンデミックを通じて世界的に大幅に減少しており、その減少幅は約30%から100%を超えていました。しかし、封鎖規制が解除された現在、同市場は大幅な成長が見込まれています。

糖尿病網膜症市場レポートハイライト

– 非増殖糖尿病網膜症セグメントは、2022年に70.5%の最大の売上シェアを占めました。糖尿病歴10年未満の患者数が多いことが、このセグメントの市場規模を大きくしました。

– 抗VEGF薬は、糖尿病網膜症の治療における効率性と有効性により、2022年に92.8%の最大売上シェアを占めました。軽度から中等度の非増殖性糖尿病網膜症の治療と早期診断におけるこれらの薬剤の高い適用性が、このセグメントの成長を導く主な要因の一つです。

– アジア太平洋地域では、予測期間中に最も高いCAGRが見込まれます。同地域の人口の多さ、糖尿病有病率の高さ、高齢者人口の増加が市場を強化する可能性が高くなっています。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Management
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Management outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of diabetes
3.4.1.2. Growing geriatric population
3.4.1.3. Increasing prevalence of blindness due to diabetes
3.4.2. Market restraint analysis
3.4.2.1. Lack of accurate diagnosis
3.4.2.2. Adverse effect on treatment
3.5. Diabetic Retinopathy Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Proliferative Diabetic retinopathy
4.1.2. Non-proliferative diabetic retinopathy
4.2. Type Market Share, 2022 & 2030
4.3. Segment Dashboard
4.4. Global Diabetic Retinopathy Market by Type Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Proliferative Diabetic retinopathy
4.5.2. Non proliferative diabetic retinopathy
Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Anti-VEGF
5.1.2. Intraocular Steroid Injection
5.1.3. Laser Surgery
5.1.4. Vitrectomy
5.2. Management Market Share, 2022 & 2030
5.3. Segment Dashboard
5.4. Diabetic Retinopathy Market by Management Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Anti-VEGF
5.5.1.1. Anti- VEGF estimates and forecast 2018 to 2030 (USD Million)
5.5.2. Intraocular Steroid Injection
5.5.2.1. Intraocular steroid injection estimates and forecast 2018 to 2030 (USD Million)
5.5.3. Laser Surgery
5.5.3.1. Laser Surgery market estimates and forecast 2018 to 2030 (USD Million)
5.5.4. Vitrectomy
5.5.4.1. Vitrectomy market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis
6.1. Regional market share analysis, 2022 & 2030
6.2. Regional Marketplace: Key Takeaways
6.3. North America
6.3.1. SWOT Analysis
6.3.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.3.3. U.S.
6.3.3.7. Country Dynamics
6.3.3.2. Country Variables
6.3.3.3. Competitive Landscape
6.3.3.4. Regulatory/Reimbursement Framework
6.3.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.3.4. Canada
6.3.4.1. Country Dynamics
6.3.4.2. Country Variables
6.3.4.3. Competitive Landscape
6.3.4.4. Regulatory/Reimbursement Framework
6.3.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. SWOT Analysis
6.4.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.3. UK
6.4.3.1. Country Dynamics
6.4.3.2. Country Variables
6.4.3.3. Competitive Landscape
6.4.3.4. Regulatory/Reimbursement Framework
6.4.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.4. Germany
6.4.4.1. Country Dynamics
6.4.4.2. Country Variables
6.4.4.3. Competitive Landscape
6.4.4.4. Regulatory/Reimbursement Framework
6.4.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.5. France
6.4.5.1. Country Dynamics
6.4.5.2. Country Variables
6.4.5.3. Competitive Landscape
6.4.5.4. Regulatory/Reimbursement Framework
6.4.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.6. Italy
6.4.6.1. Country Dynamics
6.4.6.2. Country Variables
6.4.6.3. Competitive Landscape
6.4.6.4. Regulatory/Reimbursement Framework
6.4.6.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.7. Spain
6.4.7.1. Country Dynamics
6.4.7.2. Country Variables
6.4.7.3. Competitive Landscape
6.4.7.4. Regulatory/Reimbursement Framework
6.4.7.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Country Dynamics
6.4.8.2. Country Variables
6.4.8.3. Competitive Landscape
6.4.8.4. Regulatory/Reimbursement Framework
6.4.8.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.9. Sweden
6.4.9.1. Country Dynamics
6.4.9.2. Country Variables
6.4.9.3. Competitive Landscape
6.4.9.4. Regulatory/Reimbursement Framework
6.4.9.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.4.10. Norway
6.4.10.1. Country Dynamics
6.4.10.2. Country Variables
6.4.10.3. Competitive Landscape
6.4.10.4. Regulatory/Reimbursement Framework
6.4.10.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. SWOT Analysis
6.5.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.3. Japan
6.5.3.1. Country Dynamics
6.5.3.2. Country Variables
6.5.3.3. Competitive Landscape
6.5.3.4. Regulatory/Reimbursement Framework
6.5.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.4. China
6.5.4.1. Country Dynamics
6.5.4.2. Country Variables
6.5.4.3. Competitive Landscape
6.5.4.4. Regulatory/Reimbursement Framework
6.5.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.5. India
6.5.5.1. Country Dynamics
6.5.5.2. Country Variables
6.5.5.3. Competitive Landscape
6.5.5.4. Regulatory/Reimbursement Framework
6.5.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.6. Australia
6.5.6.1. Country Dynamics
6.5.6.2. Country Variables
6.5.6.3. Competitive Landscape
6.5.6.4. Regulatory/Reimbursement Framework
6.5.6.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.7. Thailand
6.5.7.1. Country Dynamics
6.5.7.2. Country Variables
6.5.7.3. Competitive Landscape
6.5.7.4. Regulatory/Reimbursement Framework
6.5.7.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.5.8. South Korea
6.5.8.1. Country Dynamics
6.5.8.2. Country Variables
6.5.8.3. Competitive Landscape
6.5.8.4. Regulatory/Reimbursement Framework
6.5.8.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. SWOT Analysis
6.6.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6.3. Brazil
6.6.3.1. Country Dynamics
6.6.3.2. Country Variables
6.6.3.3. Competitive Landscape
6.6.3.4. Regulatory/Reimbursement Framework
6.6.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6.4. Mexico
6.6.4.1. Country Dynamics
6.6.4.2. Country Variables
6.6.4.3. Competitive Landscape
6.6.4.4. Regulatory/Reimbursement Framework
6.6.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.6.5. Argentina
6.6.5.1. Country Dynamics
6.6.5.2. Country Variables
6.6.5.3. Competitive Landscape
6.6.5.4. Regulatory/Reimbursement Framework
6.6.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. SWOT Analysis
6.7.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.3. South Africa
6.7.3.1. Country Dynamics
6.7.3.2. Country Variables
6.7.3.3. Competitive Landscape
6.7.3.4. Regulatory/Reimbursement Framework
6.7.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.4. Saudi Arabia
6.7.4.1. Country Dynamics
6.7.4.2. Country Variables
6.7.4.3. Competitive Landscape
6.7.4.4. Regulatory/Reimbursement Framework
6.7.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.5. UAE
6.7.5.1. Country Dynamics
6.7.5.2. Country Variables
6.7.5.3. Competitive Landscape
6.7.5.4. Regulatory/Reimbursement Framework
6.7.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.6. Kuwait
6.7.6.1. Country Dynamics
6.7.6.2. Country Variables
6.7.6.3. Competitive Landscape
6.7.6.4. Regulatory/Reimbursement Framework
6.7.6.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.1.1. Innovators
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key customers
7.2.3. Key company market share analysis, 2022
7.2.4. Bayer AG
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Modality benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Allergan plc
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Modality benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Novartis AG
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Modality benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Oxurion NV
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Modality benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Sirnaomics, Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Modality benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Genetech
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Modality benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Alimera Sciences
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Modality benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Ampio Pharmaceuticals
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Modality benchmarking
7.2.11.4. Strategic initiatives
7.2.12. BNC Peptides
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Modality benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Kowa Company, Ltd.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Modality benchmarking
7.2.13.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 North America Diabetic Retinopathy market, by region, 2018 - 2030 (USD Mllion)
Table 3 North America Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 4 North America Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 5 U.S. Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 6 U.S. Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 7 Canada Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 8 Canada Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 9 Europe Diabetic Retinopathy market, by region, 2018 - 2030 (USD Mllion)
Table 10 Europe Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 11 Europe Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 12 U.K. Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 13 U.K. Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 14 Germany Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 15 Germany Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 16 France Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 17 France Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 18 Italy Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 19 Italy Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 20 Spain Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 21 Spain Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Million)
Table 22 Denmark Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 23 Denmark Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 24 Norway Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 25 Norway Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 26 Sweden Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 27 Sweden Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 28 Asia Pacific Diabetic Retinopathy market, by region, 2018 - 2030 (USD Mllion)
Table 29 Asia Pacific Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 30 Asia Pacific Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 31 China Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 32 China Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 33 Japan Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 34 Japan Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 35 India Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 36 India Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 37 South Korea Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 38 South Korea Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 39 Thailand Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 40 Thailand Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Million)
Table 41 Australia Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 42 Australia Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 43 Latin America Diabetic Retinopathy market, by region, 2018 - 2030 (USD Mllion)
Table 44 Latin America Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 45 Latin America Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 46 Brazil Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 47 Brazil Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 48 Mexico Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 49 Mexico Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 50 Argentina Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 51 Argentina Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 52 Middle East & Africa Diabetic Retinopathy market, by region, 2018 - 2030 (USD Mllion)
Table 53 Middle East & Africa self-monitoring devices market, by Type, 2018 - 2030 (USD Mllion)
Table 54 Middle East & Africa Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 55 South Africa Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 56 South Africa Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 57 Saudi Arabia Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 58 Saudi Arabia Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)
Table 59 UAE Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 60 UAE Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Million)
Table 61 Kuwait Diabetic Retinopathy market, by Type, 2018 - 2030 (USD Mllion)
Table 62 Kuwait Diabetic Retinopathy market, by Management, 2018 - 2030 (USD Mllion)

★調査レポート[世界の糖尿病網膜症市場2023-2030:種類別(増殖性DR、非増殖性DR)、管理別(眼内ステロイド注射、レーザー手術、硝子体手術)、地域別] (コード:GRV23JUN039)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の糖尿病網膜症市場2023-2030:種類別(増殖性DR、非増殖性DR)、管理別(眼内ステロイド注射、レーザー手術、硝子体手術)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆